Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
|Articles|March 2, 2015
Majority of Metaplastic Breast Cancers May Be Targetable
Author(s)Sherri Z. Millis, PhD
In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
Advertisement
In this video from the 32nd Annual Miami Breast Cancer Conference, Sherri Z. Millis, PhD, a molecular science liaison at Caris Life Sciences, Phoenix, Ariz., discusses a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
Advertisement
Related to this article
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5